Amneal Pharmaceuticals
AMRX
154 hedge funds and large institutions have $535M invested in Amneal Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 48 increasing their positions, 50 reducing their positions, and 21 closing their positions.
5% more capital invested
Capital invested by funds: $511M → $535M (+$24.6M)
1% more call options, than puts
Call options by funds: $2.38M | Put options by funds: $2.36M
0.04% more ownership
Funds ownership: 67.2% → 67.24% (+0.04%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 50
4% less funds holding
Funds holding: 160 → 154 (-6)
29% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.67M |
| 2 |
EP
Eversept Partners
New York
|
+$6.17M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$2.69M |
| 4 |
Russell Investments Group
London,
United Kingdom
|
+$1.72M |
| 5 |
Two Sigma Investments
New York
|
+$1.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$4.59M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
-$2.66M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$1.93M |
| 4 |
GC
Globeflex Capital
San Diego,
California
|
-$1.64M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$1.44M |
AMRX Hedge Fund Activity: Q3 2021 in Review
154 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q3 2021, worth a combined $535M — up 4.8% from $511M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of AMRX and 15 opened new positions — a net loss of 6 holders — while 50 trimmed existing stakes and 48 added.
The largest buyer was Point72 Asset Management, adding an estimated $9.67M. The largest seller was Victory Capital Management, cutting an estimated $4.59M.
- 154 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q3 2021, down from 160 in Q2 2021.
- Funds reported $535M of Amneal Pharmaceuticals stock for Q3 2021, up 4.8% quarter-over-quarter.
- 15 funds opened new Amneal Pharmaceuticals positions in Q3 2021 and 21 closed out, a net change of -6 holders.
- The largest Amneal Pharmaceuticals buyer in Q3 2021 was Point72 Asset Management, an estimated $9.67M added.
- The largest Amneal Pharmaceuticals seller in Q3 2021 was Victory Capital Management, an estimated $4.59M sold.
Based on aggregated 13F filings for Q3 2021.